Cargando…

RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy

BACKGROUND: Facioscapulohumeral dystrophy (FSHD) is caused by mutations leading to the aberrant expression of the DUX4 transcription factor in muscles. DUX4 was proposed to induce cell death, but the involvement of different death pathways is still discussed. A possible pro‐apoptotic role of DUX4 wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mariot, Virginie, Joubert, Romain, Le Gall, Laura, Sidlauskaite, Eva, Hourde, Christophe, Duddy, William, Voit, Thomas, Bencze, Maximilien, Dumonceaux, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718031/ https://www.ncbi.nlm.nih.gov/pubmed/34687171 http://dx.doi.org/10.1002/jcsm.12813

Ejemplares similares

A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2020)

Therapeutic Strategies Targeting DUX4 in FSHD
por: Le Gall, Laura, et al.
Publicado: (2020)

DUX4 Expression in FSHD Muscles: Focus on Its mRNA Regulation
por: Sidlauskaite, Eva, et al.
Publicado: (2020)

Gene Editing to Tackle Facioscapulohumeral Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2022)

Targeting the Polyadenylation Signal of Pre-mRNA: A New Gene Silencing Approach for Facioscapulohumeral Dystrophy
por: Marsollier, Anne-Charlotte, et al.
Publicado: (2018)

Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics
por: Chen, Jennifer CJ, et al.
Publicado: (2016)

DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2020)

Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?
por: Joubert, Romains, et al.
Publicado: (2020)

CRISPR mediated targeting of DUX4 distal regulatory element represses DUX4 target genes dysregulated in Facioscapulohumeral muscular dystrophy
por: Das, Sunny, et al.
Publicado: (2021)

Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments
por: Duranti, Elisa, et al.
Publicado: (2023)

A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy
por: Feng, Qing, et al.
Publicado: (2015)

Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7
por: Banerji, Christopher R S, et al.
Publicado: (2021)

Necroptosis mediates myofibre death in dystrophin-deficient mice
por: Morgan, Jennifer E., et al.
Publicado: (2018)

Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy
por: Himeda, Charis L., et al.
Publicado: (2018)

Publisher Correction: Necroptosis mediates myofibre death in dystrophin-deficient mice
por: Morgan, Jennifer E., et al.
Publicado: (2018)

Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through β-Catenin in Facioscapulohumeral Muscular Dystrophy
por: Ganassi, Massimo, et al.
Publicado: (2022)

Telomere Position Effect (TPE) Regulates DUX4 in Human Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Stadler, Guido, et al.
Publicado: (2013)

p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy
por: Bosnakovski, Darko, et al.
Publicado: (2017)

A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy
por: Jones, Takako, et al.
Publicado: (2018)

Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy
por: Bouwman, Linde F., et al.
Publicado: (2021)

DUX4 promotes transcription of FRG2 by directly activating its promoter in facioscapulohumeral muscular dystrophy
por: Thijssen, Peter E, et al.
Publicado: (2014)

Adenine base editing of the DUX4 polyadenylation signal for targeted genetic therapy in facioscapulohumeral muscular dystrophy
por: Šikrová, Darina, et al.
Publicado: (2021)

Multiple Protein Domains Contribute to Nuclear Import and Cell Toxicity of DUX4, a Candidate Pathogenic Protein for Facioscapulohumeral Muscular Dystrophy
por: Corona, Edgardo Daniel, et al.
Publicado: (2013)

Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Jones, Takako I., et al.
Publicado: (2016)

Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models
por: Nunes, Andreia M., et al.
Publicado: (2021)

Analysis of genes regulated by DUX4 via oxidative stress reveals potential therapeutic targets for treatment of facioscapulohumeral dystrophy
por: Karpukhina, Anna, et al.
Publicado: (2021)

A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4
por: Sasaki-Honda, Mitsuru, et al.
Publicado: (2018)

Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity
por: Jones, Takako I., et al.
Publicado: (2020)

Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
por: Mariot, Virginie, et al.
Publicado: (2017)

DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy
por: Shadle, Sean C., et al.
Publicado: (2017)

A Targeted Approach for Evaluating DUX4-Regulated Proteins as Potential Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics
por: Campbell, Amy E., et al.
Publicado: (2023)

Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2020)

Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy
por: Saad, Nizar Y., et al.
Publicado: (2021)

Ophthalmological findings in facioscapulohumeral dystrophy
por: Goselink, Rianne J M, et al.
Publicado: (2019)

Treatment of facioscapulohumeral muscular dystrophy with Denosumab
por: Lefkowitz, Stanley S., et al.
Publicado: (2012)

Facioscapulohumeral dystrophy: the path to consensus on pathophysiology
por: Tawil, Rabi, et al.
Publicado: (2014)

Sarcopenic Obesity in Facioscapulohumeral Muscular Dystrophy
por: Vera, Kathryn, et al.
Publicado: (2020)

Characterizing the face in facioscapulohumeral muscular dystrophy
por: Loonen, T. G. J., et al.
Publicado: (2020)

The socioeconomic burden of facioscapulohumeral muscular dystrophy
por: Blokhuis, Anna M., et al.
Publicado: (2021)

Baroreflex sensitivity in facioscapulohumeral muscular dystrophy
por: Anselmo, Miguel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4c9kdnvebk86s9qq7ub12hk614